Search
Aytu Biopharma Inc
AYTUAdd to Watchlist
2.380USD
+0.050+2.15%
Close 08-14 16:00（ET）Quotes delayed by 15 min
25.55MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Aytu Biopharma Inc is 8.00, ranking 59 out of 156 in the Pharmaceuticals industry. The average price target is 8.00, with a high of 12.50 and a low of 7.00.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
9.500
Target Price
+313.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Aytu Biopharma Inc
AYTU
3
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
32
Regeneron Pharmaceuticals Inc
REGN
30
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Aytu Biopharma Inc's expected revenue for the next quarter?
Aytu Biopharma Inc's expected revenue is 12.28M.
What is Aytu Biopharma Inc's price target?
Analysts forecast that Aytu Biopharma Inc's price target is USD 8.00, with the highest forecast at USD 12.50 and the lowest forecast at USD 7.00.
How have Aytu Biopharma IncAYTU's recent earnings per share performed?
The market expectation was USD -0.53, while Aytu Biopharma IncAYTU's earnings per share (EPS) for the previous quarter was USD -1.05. EPS for the next quarter is expected at USD -0.33.
What is the analyst rating for Aytu Biopharma Inc?
Based on the ratings of Aytu Biopharma Inc's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.